Celine M.
- Country
- France
- Department
- gastroentérologie
Research Overview
- Comparison of Vedolizumab, Filgotinib, Ustekinumab, and Infliximab as First-Line Advanced Therapy to Maintain Remission in Patients with Ulcerative Colitis
- Phase III Randomized Study of Induction Chemotherapy with Modified DCF Regimen Followed by Chemoradiotherapy vs. Standard Chemoradiotherapy in Locally Advanced Anal Squamous Cell Carcinoma
- Efficacy of Vedolizumab Versus Adalimumab Dose Intensification in Crohn's Disease Patients with Secondary Loss of Response to Adalimumab
Data & Insights
Has run more than one trial at 29 of 142 partner sites.
Specializations
Oncological Focus
The investigator specializes in treating locally advanced anal squamous cell carcinoma, with particular emphasis on exploring innovative therapeutic approaches combining chemotherapy and radiotherapy treatments.
- Advanced Cancer Management
- Combined Therapy Approaches
- Chemoradiotherapy Applications
Their research encompasses comprehensive treatment strategies for advanced-stage anal cancer patients.
Gastroenterology Expertise
The investigator demonstrates significant expertise in treating Crohn's Disease, focusing on combination therapy approaches using immunomodulators and biological agents.
- Inflammatory Bowel Disease Treatment
- Immunotherapy Applications
- Endoscopic Assessment
Their work involves evaluating therapeutic responses through advanced endoscopic techniques.
Treatment Innovation
The investigator explores novel therapeutic combinations in both oncology and gastroenterology, with particular attention to treatment optimization and patient outcomes.
- Combination Therapy Development
- Treatment Response Assessment
- Clinical Outcome Evaluation
Their research contributes to advancing treatment protocols in complex medical conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.